Boston Scientific Corp. (NYSE:BSX)’s share price reached a new 52-week high during trading on Tuesday . The company traded as high as $23.99 and last traded at $23.69, with a volume of 4,840,501 shares traded. The stock had previously closed at $23.77.

BSX has been the subject of a number of analyst reports. Needham & Company LLC raised their price target on Boston Scientific Corp. from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, April 27th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $22.00 price target on shares of Boston Scientific Corp. in a report on Wednesday, April 6th. Goldman Sachs Group Inc. raised their price target on Boston Scientific Corp. from $21.00 to $22.00 in a report on Friday, April 8th. Nomura Holdings Inc. initiated coverage on Boston Scientific Corp. in a report on Thursday, March 17th. They issued a “buy” rating and a $22.00 price target for the company. Finally, Zacks Investment Research raised Boston Scientific Corp. from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a report on Tuesday, April 12th. Four research analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company. Boston Scientific Corp. currently has a consensus rating of “Buy” and an average price target of $23.44.

The company has a 50-day moving average of $22.89 and a 200-day moving average of $19.79. The company’s market cap is $32.13 billion.

Boston Scientific Corp. (NYSE:BSX) last issued its earnings results on Wednesday, April 27th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.04. The firm earned $1.96 billion during the quarter, compared to the consensus estimate of $1.91 billion. The company’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.21 EPS. Analysts expect that Boston Scientific Corp. will post $1.09 EPS for the current year.

In related news, EVP Timothy A. Pratt sold 39,927 shares of the company’s stock in a transaction on Wednesday, April 27th. The shares were sold at an average price of $21.40, for a total value of $854,437.80. Following the completion of the transaction, the executive vice president now owns 291,724 shares of the company’s stock, valued at approximately $6,242,893.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael F. Mahoney sold 100,000 shares of the company’s stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $22.12, for a total transaction of $2,212,000.00. Following the completion of the transaction, the chief executive officer now directly owns 1,632,577 shares of the company’s stock, valued at approximately $36,112,603.24. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently modified their holdings of BSX. TD Asset Management Inc. increased its position in shares of Boston Scientific Corp. by 2.6% in the fourth quarter. TD Asset Management Inc. now owns 606,531 shares of the company’s stock valued at $11,184,000 after buying an additional 15,100 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Boston Scientific Corp. by 7.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 57,502 shares of the company’s stock valued at $1,061,000 after buying an additional 3,945 shares in the last quarter. Commerzbank Aktiengesellschaft FI increased its position in shares of Boston Scientific Corp. by 101.6% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 87,815 shares of the company’s stock valued at $1,619,000 after buying an additional 44,248 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Boston Scientific Corp. by 5.5% in the fourth quarter. ProShare Advisors LLC now owns 236,453 shares of the company’s stock valued at $4,360,000 after buying an additional 12,261 shares in the last quarter. Finally, Comerica Bank increased its position in shares of Boston Scientific Corp. by 0.4% in the fourth quarter. Comerica Bank now owns 333,885 shares of the company’s stock valued at $5,820,000 after buying an additional 1,206 shares in the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.